Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study

Koopmans, Klaas Pieter; Vries, Elisabeth G.E. de; Kema, Ido P.; Elsinga, Philip H.; Neels, Oliver; Sluiter, Wim J.; Horst-Schrivers, Anouk N A van der; Jager, Pieter L.

doi:10.1016/s1470-2045(06)70801-4

Cited by 223 publications

(120 citation statements)

References 24 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…It has been stated that 18 F-FDG could be better in detecting liver lesions [10,11] because of physiologic 131 I-MIBG distribution in the liver, this hypothesis was not confirmed by our results in 3 patients having hepatic lesions.…”

Section: Resultscontrasting

confidence: 66%

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Fawzy

Moussa²,

Hamouda

et al. 2015

JST

View full text Add to dashboard Cite

Introduction and aim: Several studies report conflicting results about 18 F-FDG/PET and MIBG scans and their diagnostic as well as prognostic significance in children with neuroblastoma. The current study was meant to evaluate both modalities and to compare them in relation to standardized modes of evaluation. Results: FDG/PET showed good results in detecting NB at all sites. FDG/PET also showed a higher sensitivity and specificity, and a better PPV/NPV than MIBG which was not statistically significant. Concordance between paired scans (MIBG, and PET) was found in 55.7% of cases (Kappa=0.001) for primary tumor site, and in 7% for bone and 19.4% for bone marrow. The significance of concordance between both modalities was only demonstrated for metastatic boney lesions. There were 13 patients having stage III neuroblastoma (43.3%) while 17 patients (56.7%) were having stage IV disease. 23 Patients were categorized as high risk (76.7%) while 7 patients (23.3%) were intermediate risk. Both, PET/CT scan and MIBG were more sensitive in detecting disease at stage IV than stage III. Patients and Conclusion:18 F-FDG/PET scan can be used effectively in both diagnosis and management decisions for children with neuroblastoma, it is a good complementary tool especially in detecting bone metastasis, although further clinical trials must agree on definite analytical aspects between both modalities.

show abstract

Section: Resultscontrasting

confidence: 66%

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Fawzy

Moussa²,

Hamouda

et al. 2015

JST

View full text Add to dashboard Cite

show abstract

“…Koopmans et al [74] evaluated 53 patients in a prospective single-center diagnostic accuracy study using 18F-DOPA PET, conventional CT and SRS without any CT correlation, and reported that 18F-DOPA PET detected more lesions, more positive regions and more lesions per region as compared with the other modalities. Reported sensitivities at the patient, region and lesion levels were 100%, 95% and 96%, respectively.…”

Section: F18-dihydroxyphenylalanine Pet/ctmentioning

confidence: 99%

Imaging of gastroenteropancreatic neuroendocrine tumors

Tan

Tan²

2011

WJCO

View full text Add to dashboard Cite

Imaging of gastroenteropancreatic neuroendocrine tumors can be broadly divided into anatomic and functional techniques. Anatomic imaging determines the local extent of the primary lesion, providing crucial information required for surgical planning. Functional imaging, not only determines the extent of metastatic disease spread, but also provides important information with regard to the biologic behavior of the tumor, allowing clinicians to decide on the most appropriate forms of treatment. We review the current literature on this subject, with emphasis on the strengths of each imaging modality.

show abstract

“…Recent years have seen the development of other radiopharmaceuticals suitable for detecting NETs [14][15][16], but under certain circumstances, F-18-FDG PET can also be of diagnostic importance in NET patients with high proliferation index [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

The influence of Ki-67 proliferation index on Tc-99m-EDDA-HYNIC-TOC somatostatin receptor scintigraphy in patients with carcinoids

et al. 2014

View full text Add to dashboard Cite

Abstract:The aim of this paper is to determine the influence of Ki-67 proliferation index on somatostatin receptor scintigraphy (SSRS) with Tc-99m-EDDA-HYNIC-TOC (Tc-99m-Tektrotyd) somatostatin analogue in patients with carcinoid tumors. Sixty-one patients (31 female, 30 male; age range: 33-76 years) were examined: 13 patients highly suspected of having a carcinoid, and 48 patients who had undergone the surgical removal of the tumor. Whole body SSRS at 4 h postinjection, spot scintigrams and SPECT of the selected regions were obtained for all patients. Tc-99m-Tektrotyd scintigraphy was classified as true positive in 26 out of 30 and true negative in 24 out of 28 patients. The sensitivity of Tc-99mTc-Tektrotyd scintigraphy was found to be as high as 94.74% in the group of patients with low mitotic index Ki67 (<2%), and it progressively decreased in patients with higher mitotic index (77.78% for Ki67 2-15% and 20% for Ki67% >20%). The likelihood of Tc-99m-Tektrotyd scan being positive when a carcinoid is present was found to be inversely proportional to the value of Ki67 proliferation index. The results showed that Tc-99m-Tektrotyd SSRS is a sensitive method for diagnosing and staging patients with well-differentiated carcinoid tumors. However, in poorly differentiated tumors with high Ki67 proliferation index, additional analyses are necessary for precise staging.

show abstract

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study

Cited by 223 publications

References 24 publications

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Imaging of gastroenteropancreatic neuroendocrine tumors

The influence of Ki-67 proliferation index on Tc-99m-EDDA-HYNIC-TOC somatostatin receptor scintigraphy in patients with carcinoids

Contact Info

Product

Resources

About